Symvivo

Symvivo

Symvivo is a biotechnology company developing cancer gene therapies for treating cancer.

Symvivo is a biotechnology company developing cancer gene therapies for treating cancer that is headquartered in Burnaby, British Columbia and was founded in 2013 by Alexander Graves.

The company is also developing oral DNA vaccines for diseases such as COVID-19, or even genetic diseases. Some of their programs are designed to treat oncological diseases, ischemic heart disease, and other rare diseases. Symvivo is taking part in research and development to prevent COVID-19, and are utilizing their DNA vaccine candidate bacTRL-Spike.

BacTRL-Spike is designed to potentially protect large populations from various emergent pathogens faster than an injectable vaccine. The gene therapy is designed around the limitations of standard gene delivery systems such as accommodating larger and multi-genes, controlling immune responses, or even targeting tissues.

Within oncology, the platform allows for the colonization of solid hypoxic tumors and the establishment of living bio-factories within tumors, which re-programs the tumors physiology. With infectious diseases the platform provides a passage for a bacterial vector containing plasmid DNA.

Timeline

November 24, 2020

Symvivo Corporation announces research collaboration with Janssen.

People

Name
Role
LinkedIn

Further reading

Title
Author
Link
Type
Date

Challenge to Change: Biotech scientist gets the business skills to take his innovations to market

UBC Sauder

Web

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
BioSpace
November 24, 2020
BioSpace
Symvivo Corporation, a clinical-stage biotechnology company advancing a proprietary bacTRLTM gene delivery platform, announced today that it has entered into a research collaboration with Janssen Biotech, Inc. (Janssen), one of the Pharmaceutical Companies of Johnson & Johnson

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.